December 1, 2020

FDA Approves First PSMA-Targeted PET Imaging Drug for Prostate Cancer

On December 1, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.